{{drugbox | | IUPAC_name = (2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{1oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate | image = Taxol.svg | width = 350 | image2 = Taxol(Paclitaxel)3D.png | CAS_number = 33069-62-4 | ChemSpiderID = 10368587 | ATC_prefix = L01 | ATC_suffix = CD01 | ATC_supplemental =
ATC: CD03 (paclitaxel poliglumex) | PubChem = 36314 | DrugBank = APRD00259 | C=47 | H=51 | N=1 | O=14 | molecular_weight = 853.906 g/mol | bioavailability = 6.5% (oral) | protein_bound = 89 to 98% | metabolism = Hepatic (CYP2C8 and CYP3A4) | elimination_half-life = 5.8 hours | excretion = Fecal and urinary | pregnancy_AU = | pregnancy_US = D | pregnancy_category = | legal_status = Rx-=only | routes_of_administration = iv }} Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific Yew tree, Taxus brevifolia and named it 'taxol'. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to 'paclitaxel' and the BMS compound is sold under the trademark 'TAXOL'. In this formulation, paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments